Idorsia (CHIX:IDIAZ) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


CHIX:IDIAZ Idorsia Ltd CHIX:IDIAZ
63 GF Score
Price CHF6.02
GF Value CHF2.88
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Idorsia Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Idorsia's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

CHIX:IDIAZ vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Idorsia's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Idorsia Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Idorsia's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Idorsia's Margin of Safety % (DCF Earnings Based) falls into.


CHIX:IDIAZ
63GF Score
Idorsia Ltd CHIX:IDIAZ
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Idorsia (CHIX:IDIAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Idorsia stock appears to be overvalued. The current stock price of CHF6.02 is trading 109% above its estimated GF Value™ of CHF2.88. GuruFocus considers Idorsia to be Significantly Overvalued.

Key valuation signals for CHIX:IDIAZ:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: CHF2.88 vs. price of CHF6.02 (109% above fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the CHIX:IDIAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Idorsia Business Description

Address Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
63GF Score

Get the complete analysis for CHIX:IDIAZ

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF6.02
Price
CHF2.88
GF Value